Friday, April 25, 2008

The DNA Network

The DNA Network

First reading on Tomorrow's Table [Tomorrow's Table]

Posted: 25 Apr 2008 06:59 PM CDT

Last night Raoul and traveled to Mrs. Dalloway's bookstore in Berkeley to discuss our book "Tomorrow's Table". Here are some questions/comments from the audience and our answers:

Beth Greenfield, stellar yoga teacher in Berkeley: " It does seem like a very complicated subject when you consider everyone's opinions and prejudices. How do you prove that GE produce is safe to consume and grow? And would diehard anti-GE people even listen? You made a good case when you compared it to GM produce and that it is considered okay. But I guess people still think "don't fool with Mother Nature".

Unknown citizen "How can you prove the nutritional content of GE food is not damaged?"
Pam: "Of all the concerns about GE food, this question of risk presents the biggest worry for the most people. The U.S. National Academy of Science addressed a broader question by asking, 'Is the process of adding genes to our food by genetic engineering any more risky than adding genes by traditional breeding?' The answer is no. Virtually everything we eat has been genetically modified in someway, and virtually every food we eat poses some kind of risk, albeit a very, very small risk. The NAS committee determined that both the process of GE and conventionalbreeding pose similar risks of unintended consequences."

Jon Agee, author of children's picture books, husband of Audrey and idol of our children. "I don't think you reached the woman that asked about nutrition. She left early and did not buy a book".

Old friend of Raoul's, Tom Schwartz, Berkeley: "I heard that transgenes were found in traditional corn varieties in Mexico, is this a problem?"
Pam: "In a study of corn landraces in Northern Oaxaca, Ignacio Chapela, a professor at the University of California, Berkeley, published a paper in Nature providing evidence for the presence of transgenic DNA in these landraces. The published results ignited an explosion of worldwide publicity because transgenic corn had never been approved for cultivation in Mexico and there was concern that the presence of transgenes might compromise the genetic diversity of these landraces. Although the results presented in the initial publication were widely disputed and then refuted by a larger peer-reviewed study, the paper prompted an important debate over possible biological, economic, and cultural implications of gene flow. These issues are increasingly important because Mexican corn growers want to use GE to improve productivity and poor consumers rely on this staple.

Each crop GE or conventionally bred variety needs to be evaluated on a case-by-case basis as to whether gene flow will create a problem in a particular environment. In California's central valley it is not such an issue, because most of the crops grown here (GE and not GE) do not cross-pollinate native species nearby. It is as if California were a large, oval-shaped, flat-bottomed platter with steep, slippery sides holding all the domesticated crop plants at the bottom."

Rick Ronald, favorite younger brother: "You should cut the talk in half and leave more time for questions- that part was hot."

Unknown "I hear that the farmer Percy Schmeiser was sued by Monsanto and it was nothis fault. It sounds like he had a terrible time.
Pam, passing on the question to an audience member. "Peggy (UCB professor and creator of ucbiotech.org), would you be willing to comment?"
Peggy: "I have heard Percy talk and read some of the court documents. The court found that Schmeiser had either known or ought to have known that he had planted Roundup Ready canola in 1998. The court also found that by selling the seed harvested in 1998 Percy further infringed Monsanto's patent."

Mateo Burtch, tech writer and funny guy "You spelled my name wrong in the acknowledgements"

Mrs. Dalloway's staffer 30 minutes after closing time "Would you please leave now?"

Disclosing Risk: Good Communication or "Doctor-Knows-Best"? [PredictER Blog]

Posted: 25 Apr 2008 03:58 PM CDT

A newly published paper from PredictER's Peter H. Schwartz and Eric M. Meslin, examines the challenges of balancing beneficence and the respect for autonomy in preventive and predictive medicine. In "The ethics of information: absolute risk reduction and patient understanding of screening" (J Gen Intern Med. 2008 Apr 18; [Epub ahead of print] | PMID: 18421509) the authors question whether providing absolute probabilities of risk based, for example, on genetic screening for breast cancer, is always in the best interest of the patient's health. While many argue the respect for the patient's autonomy demands that risk is communicated numerically or graphically, Schwartz and Meslin argue that the disclosures should be made "in the light of careful consideration of patient understanding and possible impacts on uptake and well-being".

Happy DNA Day!!! [The Gene Sherpa: Personalized Medicine and You]

Posted: 25 Apr 2008 03:24 PM CDT

Lots of great posts on this DNA Day. First, I would like to tell Misha at GenomeBoy....Doubting Thomas was eventually one of the greatest supporters.... This is in response to my post yesterday. I...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

SimpleGenetics(TM) for DNA day [www.cancer-genetics.com]

Posted: 25 Apr 2008 03:13 PM CDT


Happy DNA day! This year in Europe we celebrate it for the first time officially. What a coincidence - yeasterday I’ve received gene T-shirt with mapped 1st chromosome from the magazine Science - wearing it all this day :)

On this occasion I would like to introduce you to SimpleGenetics(TM) genetic test reviews - it could be an independent wiki-based resource dedicated to the provision of reviews and unbiased information about commonly available genetic tests, its clinical validity and utility.

The project aims to improve the quality and accessibility of information regarding genetic tests and help to make informed choice decision for physicians and/or patients.

The information would be reviewed and edited by registered clinicians or scientists working in clinical genetic settings.

There is a preference for objective, scientific evidence-based, comprehensive reviews of clinical evidence and appreciate contribution of both genetic testing companies, clinicians and users to satisfy these goals.

I made this draft in February, and there is some information about Mammaprint available already. Let me know what you think about it and future involvement/contribution/etc. possibility.

Check out at SimpleGenetics.com

Health World Web: A Health 2.0 Platform [ScienceRoll]

Posted: 25 Apr 2008 02:21 PM CDT


Health World Web, Inc., a Jacksonville, FL company, that tries to create a new, more interactive platform for patients and medical professionals as well. It offers emotional support, non-medical advice; ratings, reviews and recommendations for local doctors, dentists and chiropractors. The database now consists of more than a hundred patient communities and nearly 1.5 million doctors.

An excerpt from the mission statement:

The primary focus of our current site is to enable users to communicate with other patients, provide and share emotional support within relevant communities as well as facilitate the exchange of recommendations for local doctors, dentists, chiropractors, physical therapists and alternative medicine providers. Our users can create or join specialized communities and discuss their health issues with a local person or an entire planet, directly connect with other members in the forums area, and get recommendations about the best health care available in their neighborhood or across the country.

And here is a video describing the main goals and features of the site. If you mix social networking and doctor search with a twist, it is called HealthWorldWeb.com

More at Health World Web

This is a cross-post from Medgadget.

Personalized Medicine: Real Clinical Examples! [ScienceRoll]

Posted: 25 Apr 2008 02:00 PM CDT


There are more than 60 articles in the personalized medicine category on my blog and I have a page dedicated to this emerging field of medicine. I also wrote a summary about it. But now it is time to show you some real examples; some cases and ideas that could play a major role in the future of healthcare. Genetic tests and pharmacogenetic variants which are used in clinical practice or will be used soon. I would like to consider this post as a continuously developing collection or database of examples and ideas. Please let me know if you know other examples of personalized medicine that were published in a peer-reviewed journal.

onepill50.JPG

  • Azathioprine (AZA) and 6-mercaptopurine (6- MP) in inflammatory bowel disease¹:

Thiopurine S-methyltransferase (TPMT) is a key metabolic enzyme for azathioprine (AZA) and 6-mercaptopurine (6- MP), 2 widely used medications in the treatment of IBD. AZA is metabolized to 6-MP and subsequently 6-thioguanine (6-TG), the active metabolite. 6-MP can be inactivated by either TPMT or xanthine oxidase to nontoxic products. SNPs in the TPMT gene reduce TPMT activity, shunting metabolism to 6-TG and increasing toxicity, particularly neutropenia; TPMT deficiency can serve to lower the starting dose or to alternative therapies. TPMT enzyme (phenotype) activity in red blood cells and genotype testing to detect the major mutations that lower TPMT activity are both available and used by most physicians in the United Kingdom, including 75% of gastroenterologists. Approved by the US Food and Drug Administration (FDA), TPMT testing has led to relabeling for AZA and 6-MP to provide genomic information to providers.

  • Methotrexate in Crohn’s disease¹:

This pharmacogenetic test is used in IBD treatment. The SNPs of methylenetetrahydrofolate reductase (MTHFR) are associated with increased toxicity of methotrexate used to treat Crohn’s disease.

  • Her2/neu positivity in breast cancer²:

HER2/neu is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor.

Human epidermal growth factor receptor 2-overexpressing breast cancer is known to be associated with particularly aggressive disease and poor prognosis. On the other hand, human epidermal growth factor receptor 2/neu overexpression may predict response to endocrine therapy or chemotherapy. Nevertheless, trastuzumab increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress human epidermal growth factor receptor 2. In the pretrastuzumab era, retrospective analyses have shown that human epidermal growth factor receptor 2 overexpression is an adverse prognostic factor associated with an increased risk of disease recurrence and death. In the trastuzumab era, this drug has changed the natural history of human epidermal growth factor receptor 2-positive breast cancer, either in the metastatic or, according to the most recent evidences, in the adjuvant setting.

  • VKORC1 and CYP2C9 polymorphisms in warfarin metabolism³:

Warfarin is the most widely prescribed oral anticoagulant, but there is greater than 10-fold interindividual variability in the dose required to attain a therapeutic response. Pharmacogenetic analysis of two genes, the warfarin metabolic enzyme CYP2C9 and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose. Possession of CYP2C9*2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean warfarin dose. Several single nucleotide polymorphisms (SNPs) in VKORC1 are associated with warfarin dose across the normal dose range. Haplotypes based on these SNPs explain a large fraction of the interindividual variation in warfarin dose, and VKORC1 has an approximately three-fold greater effect than CYP2C9. Algorithms incorporating genetic (CYP2C9 and VKORC1), demographic, and clinical factors to estimate the warfarin dosage, could potentially minimize the risk of over dose during warfarin induction.

FDA approved it last year.

  • CYP2C19 polymorphism in Helicobacter pylori–related disorders¹:

The treatment of H pylori infection requires a multidrug regimen that contains multiple antibiotics plus proton pump inhibitors (PPIs) or histamine-2 receptor blockers for eradication. Pharmacogenetic studies have revealed potentially important host genetic variability to PPI response; CYP2C19 SNPs define patients as rapid (RM), intermediate (IM), or poor metabolizers (PM). Asian populations demonstrate a higher frequency of PMs, higher PPI efficacy, and may have better H pylori eradication at standard doses. With omeprazole the most sensitive to CYP2C19 variation, H pylori eradication rates may vary with specific PPIs and are generally lower; higher PPI doses may be needed in RMs. Pretreatment PPI genotyping improves H pylori eradication rates but cost effectiveness has not yet been studied.

  • UGT1A1 polymorphism in irinotecan treatment of colon cancer¹:

Irinotecan, a topoisomerase I inhibitor, is a first-line treatment for colon cancer, alone or in combination. Delivered as a prodrug, irinotecan must be metabolized to SN-38, an active compound that is then inactivated by UDP glucuronosyltransferases (UGTs). Variability in one of these enzymes, UGT1A1, leads to accumulation of SN-38 and increased toxicity, most notably neutropenia and diarrhea. Specific UGT1A1*28 and UGT1A1*6 (in Asians) SNPs markedly increase irinotecan toxicity risk. Further, Gilbert's syndrome, a benign disorder of indirect hyperbilirubinemia, is caused by the same mutations and predicts irinotecan toxicity. The FDAhas relabeled irinotecan and approved tests for UGT1A1*28 SNPs; UGT1A1*6 analysis will be additionally needed for Asian patients. UGT1A1 testing may prevent severe irinotecan toxicity through dose reduction or switching to an alternative oxaloplatin-based regimens. For oxaloplatin, genetic testing for SNPs in the DNA repair genes XRCC1, ERCC1, and ERCC2 and glutathione-S-transferase (GST), predict better response, although diagnostic tests for these mutations are not yet routinely available.

  • Polymorphism of 5-fluorouracil in the treatment of gastric cancer¹:

Even with the arrival of new biologic agents against colon cancer, 5-fluorouracil (5-FU) remains a mainstay of treatment but carries a high risk of adverse effects. Multiple SNPs in DPYD decrease DPY enzyme activity, which would normally inactivate 5-FU and its orally administered prodrug capecitabine; heterozygotes for these genetic variants reach a prevalence of 3%–5%. Cost effectiveness will determine the usefulness of DPD enzyme assays or genotype testing for DPYD variants prior to using 5-FU or capecitabine. In addition, genetic variants in the thymidylate synthase promoter lead to decreased tumor response to 5-FU–based regimens. Pharmacogenetic lessons learned in colon cancer treatment seem to apply to gastric cancer.

References:

  1. Patel KK, Babyatsky MW. Medical Education: A Key Partner in Realizing Personalized Medicine in
    Gastroenterology
    . Gastroenterology. 2008 Mar;134(3):656-61.
  2. Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol. 2007 Feb;19(1):56-62.
  3. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res. 2007;120(1):1-10. Epub 2006 Dec 11.

Celebrate DNA Day! [DNA Direct Talk]

Posted: 25 Apr 2008 01:02 PM CDT

Happy DNA Day, everybody! Today is great opportunity to celebrate DNA — whether you’re a student, an expert, a science lover or a novice. So put on your DNA t-shirts, get out there and hug a helix. (I’d love be a grown-up kid at Dr. Barry Star’s events at the Tech Museum of Innovation today, [...]

Phylogeny Friday -- 25 April 2008 [evolgen]

Posted: 25 Apr 2008 10:00 AM CDT

Duh! That's Obvious, Edition

Take a look at this mastodon skeleton:

mastodon_skeleton.JPG

Does it look like anything you recognize? Perhaps a large terrestrial mammal with big tusks. If you said "elephant" you win. The prize: nothing.

ResearchBlogging.org

That is half of the conclusion from a recent paper in Science (doi:10.1126/science.1154284). Really. The other half: birds and dinosaurs are pretty closely related. Or, more specifically, birds and Tyrannosaurus rex -- THE COOLEST MOST AWESOMEST OF ALL DINOSAURS EVER!! -- are closely related. And, for this, they get a Science paper.

Now, the way they did this is pretty damn cool: they sequenced proteins from T. rex bones. But that was reported last year (doi:10.1126/science.1137614) in the paper where they screwed up the species name in the title (they got it right this time around). Anyway, some of the same people took those sequences and, along with some other sequences that they mined from various databases, constructed a phylogenetic tree of vertebrates.

Read the rest of this post... | Read the comments on this post...

Managing Digital Gene Expression Workflows with FinchLab [FinchTalk]

Posted: 25 Apr 2008 08:25 AM CDT

Last Wed (4/23) Illumina hosted a Geospiza presentation featuring how FinchLab supports mRNA tag profiling experiments. We had a great turnout and the presentation is posted on the Illumina web...

Happy DNA Day! [Eye on DNA]

Posted: 25 Apr 2008 07:04 AM CDT

Be a nerd and celebrate National DNA Day with us!

DNA Diagnostics Center has two DNA Day eCards–Happy DNA Day Helix Flower and Do The Twist on DNA Day–in honor of the event. (HT: DNA Network member The DNA Testing Blog’s Top Ten Things to Do on DNA Day!)

dna-flowerdna-twist

The National Human Genome Research Institute has more activities planned for National DNA Day including a live online chatroom and DNA Day speaker presentations.

Birds and dinosaurs, collagen, and Huxley. [Genomicron]

Posted: 25 Apr 2008 07:01 AM CDT

I have already blogged about this topic in a short post [Yet another link between dinosaurs and birds], so I will just point out the existence of another paper along these lines using phylogenetic analyses of collagen amino acid sequences recovered from T. rex fossils to demonstrate a close affinity between theropod dinosaurs and birds (Organ et al. 2008), a link first proposed by T.H. Huxley in 1868. This newest analysis was led by Chris Organ, who also did the dinosaur cell/genome size estimation study (Organ et al. 2007; Zimmer 2007). They also looked at mastodons. The data from mastodons and dinosaur aren't new (Asara et al. 2007; Schweitzer et al. 2007) -- the main update is the inclusion extant species and of a phylogenetic component.


There are plenty of news stories about it, including the following.

Molecular Analysis Confirms Tyrannosaurus Rex's Evolutionary Link To Birds (ScienceDaily)

From T. Rex to Chicken: The Dino-Bird Connection(Discovery News)

T. rex confirmed as great granddaddy of all birds (New Scientist)

Phylogenetic Tree: Dinosaurs, Alligators And ... Ostriches? (Scientific Blogging)

Gunk in T. Rex Fossil Confirms Dino-Bird Lineage (LiveScience)


Finally, a reminder about how species names should be listed.
_______

References

Asara, J.M., M.H. Schweitzer, L.M. Freimark, M. Phillips, and L.C. Cantley. 2007. Protein sequences from mastodon and Tyrannosaurus rex revealed by mass spectrometry. Science 316: 280-285.

Huxley, T.H. 1868. On the animals which are most nearly intermediate between birds and the reptiles.
Annals and Magazine of Natural History, Series 4, 2: 66-75.

Organ, C.L., A.M. Shedlock, A. Meade, M. Pagel, and S.V. Edwards. 2007. Origin of avian genome size and structure in non-avian dinosaurs. Nature 446: 180-184.

Organ, C.L., M.H. Schweitzer, W. Zheng, L.M. Freimark, L.C. Cantley, and J.M. Asara. 2008. Molecular phylogenetics of mastodon and Tyrannosaurus rex. Science 320: 499.

Schweitzer, M.H., Z. Suo, R. Avci, J.M. Asara, M.A. Allen, F.T. Arce, and J.R. Horner. 2007. Analyses of soft tissue from Tyrannosaurus rex suggest the presence of protein. Science 316: 277-280.

Zimmer, C. 2007. Jurassic genome. Science 315: 1358-1359.

Biomonitors [Sciencebase Science Blog]

Posted: 25 Apr 2008 07:00 AM CDT

Autumnal grasses

Keeping a weather eye on atmospheric pollution is a large-scale, costly and time-consuming activity. However, there just happens to be a vast network of self-contained, self-powered units around the globe that can respond to the presence of toxins, radioactive species, atmospheric particulates and other materials in the environment and could be used to build up a local, national or international picture of environmental conditions - the world’s plants, mosses, and lichens.

In a forthcoming special issue of the International Journal of Environment and Pollution (2008, Volume 32, Issue 4), researchers from various fields explain how living organisms can be used to track the dispersal of atmospheric pollutants, particulates, and trace elements. They also explain how plants and other so-called biomonitors have been validated across the globe.

Writing in an editorial for the IJEP special issue chemist Borut Smodiš, a senior research associate at the Jožef Stefan Institute, in Ljubljana, Slovenia, explains how biomonitoring can be used in environments where a technological approach to monitoring is not only difficult and costly but may be impossible. “Biomonitoring allows continuous observation of an area with the help of bioindicators, an organism (or part of it) that reveals the presence of a substance in its surroundings with observable and measurable changes (e.g. accumulation of pollutants), which can be distinguished from the effects of natural stress.”

Smodiš points to numerous other advantages of biomonitoring: “Simple and inexpensive sampling procedures allow a very large number of sites to be included in the same survey, permitting detailed geographical patterns to be drawn. Biomonitoring can be an effective tool for pollutant mapping and trend monitoring in real time and retrospective analysis,” he says.

While any organism might be used as a biomonitoring agent, Smodiš points out that mosses and lichens, which lack root systems, are dependent on surface absorption of nutrients. This means that they accumulate particulates and dissolved chemical species from their surroundings rather than from the soil and so could be more appropriate biomonitors for atmospheric pollutants.

In 1998, the International Atomic Energy Agency part of the United Nations, started a Coordinated Research Project on biomonitoring. Several papers in the special issue of IJEP detail methodologies, case studies and other aspects of various projects within this initiative and point to future avenues that might be explored.

Bristling beech leaves

In the paper “Atmospheric dispersion of pollutants in Sado estuary (Portugal) using biomonitors”, Maria do Carmo Freitas of the Instituto Tecnológico e Nuclear Reactor, in Sacavém, Portugal, and colleagues used instrumental neutron activation analysis (INAA) and proton-induced X-ray emission (PIXE) to investigate pollutant levels in epiphytic lichens. They found that temperature and humidity had a more prominent effect on pollutant accumulation than wind direction or rainfall levels, which could affect the interpretation of other biomonitoring results.

Ni Bangfa of the China Institute of Atomic Energy, Beijing, and colleagues in their paper “Study on air pollution in Beijing’s major industrial areas using multielements in biomonitors and NAA techniques” used NAA to analyze three types of plant leaves from Chinese white poplar, arborvitae, and pine needles. They found that northeast Beijing is a clean area while southwest is relatively polluted.

In “Biomonitoring in the forest zone of Ghana” B.J.B. Nyarko of the Ghana Atomic Energy Commission and colleagues studied the distribution of heavy metals in agricultural, industrial and mining areas in the first survey of its kind in Ghana using lichens as biomonitors. They found that the area around gold mining regions were most heavily polluted, with arsenic, antimony, and chromium while industrial sites had raised levels of aluminum, iron, and titanium. Farming regions were much less affected by heavy metal pollutants, as one might expect.

H.Th. Wolterbeek of the Delft University of Technology, Delft, the Netherlands in ” Large-scale biomonitoring of trace element air pollution: local variance, data comparability and its relationships to human health” used biomonitoring data to determine air concentrations and metal deposition and discussed how such studies might be used in the future to correlate pollution with human health issues. Other researchers including Bernd Markert of International Graduate School Zittau, Zittau, Germany, Eiliv Steinnes of the Norwegian University of Science and Technology, in Trondheim, and their respective teams also further validated the potential of biomonitoring approaches to pollution.

Mosses lichens

While biomonitoring techniques are improving rapidly and researchers are quickly validating results at the local level, Smodiš points out that there is no single species that could be used on the global scale. Moreover, different weather conditions around the globe mean that techniques are not necessarily comparable. With that in mind, environmental sensor manufacturers may rest assured that there is still a market for their instrumentation despite the best efforts of the mosses and lichens.

Around the Blogs [Bitesize Bio]

Posted: 25 Apr 2008 04:06 AM CDT

Let’s see what’s been going on around the blogs, shall we?

Personal Development

From one whose dream of tenure track just came true:
In Which the Werewolf is Admitted to Paradise - An amusing tale of motivating students to ask questions during a teaching evaluation. The end result - paradise - the coveted tenure track job.

And from those newly in a tenure track position, a series of posts discussed -
When PIs Do Experiments: Sciencewoman, Dr. Free-Ride, Dr. Jekyll & Mrs. Hyde, PhysioProf, and JuniorProf all weighed in.

The Public and Science

The Personal Genome discussion - Sandra covers a panel discussion with some big names at the University of Washington.

Genes and the Environment - Some thoughts on the eternal “nature vs. nurture” debate, in an era of genomics and PLoS.

Science Itself (titles say it all)

How Can Chromosome Numbers Change
The Definition of Life; and, Taxonomy as We Know It
Reversing dermal aging by inhibiting NF?B
RAS is Regulated by miRNAs

Books About DNA: The Century of the Gene by Evelyn Fox Keller [Eye on DNA]

Posted: 25 Apr 2008 03:07 AM CDT

century geneThe Century of the Gene by Evelyn Fox Keller

In a book that promises to change the way we think and talk about genes and genetic determinism, Evelyn Fox Keller, one of our most gifted historians and philosophers of science, provides a powerful, profound analysis of the achievements of genetics and molecular biology in the twentieth century, the century of the gene. Not just a chronicle of biology’s progress from gene to genome in one hundred years, The Century of the Gene also calls our attention to the surprising ways these advances challenge the familiar picture of the gene most of us still entertain.

In a CBC Radio interview, Dr. Evelyn Fox Keller talks more about genes and public perception. (HT: Women in Science)

For more discussion on what is a gene, see this Genome Research article - What is a gene, post-ENCODE? History and updated definition.

…we propose a tentative update to the definition of a gene: A gene is a union of genomic sequences encoding a coherent set of potentially overlapping functional products.

DNA Network member Sandra Porter at Discovering Biology in a Digital World gave her definition of a gene last year.

The dawn of human matrilineal diversity [HENRY » genetics]

Posted: 25 Apr 2008 01:44 AM CDT

Out in the AJHG, is the next in the National Genographic line of studies. This one, by Behar et al. assesses 624 mitochondrial genomes from Khoisan hunter gatherers in Africa (doi). The abstract says:

The quest to explain demographic history during the early part of human evolution has been limited because of the scarce paleoanthropological record from the Middle Stone Age. To shed light on the structure of the mitochondrial DNA (mtDNA) phylogeny at the dawn of Homo sapiens, we constructed a matrilineal tree composed of 624 complete mtDNA genomes from sub-Saharan Hg L lineages.

We paid particular attention to the Khoi and San (Khoisan) people of South Africa because they are considered to be a unique relic of hunter-gatherer lifestyle and to carry paternal and maternal lineages belonging to the deepest clades known among modern humans. Both the tree phylogeny and coalescence calculations suggest that Khoisan matrilineal ancestry diverged from the rest of the human mtDNA pool 90,000-150,000 years before present (ybp) and that at least five additional, currently extant maternal lineages existed during this period in parallel.

Furthermore, we estimate that a minimum of 40 other evolutionarily successful lineages flourished in sub-Saharan Africa during the period of modern human dispersal out of Africa approximately 60,00070,000 ybp. Only much later, at the beginning of the Late Stone Age, about 40,000 ybp, did introgression of additional lineages occur into the Khoisan mtDNA pool. This process was further accelerated during the recent Bantu expansions. Our results suggest that the early settlement of humans in Africa was already matrilineally structured and involved small, separately evolving isolated populations.

ScienceDaily has some more breathless coverage about this - quoth Spencer Wells: Tiny bands of early humans, forced apart by harsh environmental conditions, coming back from the brink to reunite and populate the world. Truly an epic drama, written in our DNA.. Epic, indeed.

New technology for boosting vaccine efficiency [Think Gene]

Posted: 25 Apr 2008 01:22 AM CDT

One of the most pressing biomedical issues is the development of techniques that increase the efficiency of vaccines. In a paper published on April 24, 2008 in the journal Vaccine, a Massachusetts's biotechnology company, Cure Lab, Inc. has proposed a new technology for anti-viral vaccination. This technology consists of two major elements. First, each vaccine [...]

Two suppressor molecules affect 70 genes in leukemia [Think Gene]

Posted: 25 Apr 2008 01:20 AM CDT

By restoring two small molecules that are often lost in chronic leukemia, researchers were able to block tumor growth in an animal model. The research, using human chronic lymphocytic leukemia (CLL) cells, also showed that loss of the two molecules affects 70 genes, most of which are involved in critical functions such as cell growth, death, [...]

Genetic sequencing of protein from T. rex bone confirms dinosaurs’ link to birds [Think Gene]

Posted: 25 Apr 2008 01:19 AM CDT

Scientists have put more meat on the theory that dinosaurs’ closest living relatives are modern-day birds. Molecular analysis, or genetic sequencing, of a 68-million-year-old Tyrannosaurus rex protein from the dinosaur’s femur confirms that T. rex shares a common ancestry with chickens, ostriches, and to a lesser extent, alligators. The dinosaur protein was wrested from a fossil T. [...]

World Premiere of Next Generation Sequencing solution from CLC bio [Next Generation Sequencing]

Posted: 25 Apr 2008 01:00 AM CDT

Boston, USA — April 25, 2008 — On Monday, April 28, CLC bio will officially unveil their new Next Generation Sequencing solution, CLC Genomics Workbench, the first comprehensive analysis package which can analyze and visualize data from all the major Next Generation Sequencing (NGS) platforms, such as SOLiD from Applied Biosystems, 454 GS flx from [...]

Human mtDNA Diversity Before Migration Out of Africa [The Genetic Genealogist]

Posted: 25 Apr 2008 12:00 AM CDT

image Yesterday, a very interesting paper was published in the American Journal of Human Genetics by the Genographic Project Consortium entitled “The Dawn of Human Matrilineal Diversity.” The results of the study, which examined the 624 mtDNA genomes from sub-saharan Haplogroup L lineages, suggests that humanity once split into two small groups with one group in eastern Africa and the other in southern Africa, and that humanity bottlenecked into a relatively small number of individuals (as few as 2,000 based on results from a previous study). Note, as always, that these are hypotheses based upon the results of this and other studies, and will require further research to support or refute.

Two mtDNA Branches

The human mtDNA tree has two main branches, the L0 branch which includes individuals concentrated in southern and eastern Africa, and the L1′2′3′4′5′6′ branch (aka the L1′5 branch), which includes the entire remainder of humanity including non-Africans (see the figure to the left). Based upon the analysis of the 624 genomes, the researchers hypothesized that the L0 and L1′5 branches diverged into two small populations around 140,000 to 210,000 years ago, with one group settling in eastern Africa (the L1′5 branch) and the other settling in southern Africa (the L0 branch). Interestingly, the results also suggest that there was little to no intermingling of these branches for the next 50,000 to 100,000 years!

The L0 branch comprises 60% of the Khoisan people (two ethnic groups named the Khoi and the San) of Southern Africa. The L1′5 branch comprises all other branches of the mtDNA tree, which includes the N and M matrilines that eventually spread out from Africa.

Population Bottleneck

The results of the study also suggest that humanity was once comprised of a relatively small number of individuals (as few as 2,000, according to another study cited by the researchers). This was suggested because there are very few matrilineal lineages present today that split during the first 100,000 years of our species’ history, likely because they they died out or never developed in the first place. If there had been many more individuals alive at that time (with descendants alive today), scientists would expect to see more different types of lineages in Africa. This is what happened during the second 100,000 years of human history, with as many as 40 different matrilines at the time that humans left Africa to spread to the remainder of the world. As many of us know now, there is a multitude of current matrilines because of our enormous population explosion in the past few thousand years. Note, however, that this hypothesis may change if researchers suddenly discover large amounts of new matrilines present in Africa which split from the main line in the first 100,000 years.

An article in the Economist did a very good job of making the article understandable. Here is a quote from this terrific article in the Economist, which I suggest you read for yourself:

Comparing Khoi and San DNA with that of other Africans shows that the first big split in Homo sapiens happened shortly after the species emerged, 200,000 years ago. Most people now alive are on one side of that split. Most bushmen are on the other. The consortium’s analysis of which DNA "matrilines" are found where suggests that for much of its history the species was divided into two isolated populations, one in eastern Africa and one in the south of the continent, that were defined by this split. However, few other matrilineal splits from the first 100,000 years of the species’s history have survived to the present day.

This suggests the early human population was tiny (so the opportunities for new matrilines to evolve in the first place were limited) and reinforces the idea that Homo sapiens may have come close to extinction (eliminating some matrilines that did previously exist). Indeed, there may, at one point, have been as few as 2,000 people left to carry humanity forward.

This shrinkage coincides with a period of prolonged drought in eastern Africa, and was probably caused by it. The end of the drought, however, was followed by the appearance of many new matrilines that survive to the present day. The researchers estimate that by 60,000-70,000 years ago, the period when the exodus that populated the rest of the world happened, as many as 40 such groups were flourishing in Africa—though that migration involved only two of these groups.

For more information, check out the following sources:

Your personal health: The Personal Genome [business|bytes|genes|molecules]

Posted: 24 Apr 2008 10:29 PM CDT

An image of a 1901 examination in the faculty of medicine.Last evening, I had a chance to attend an interesing panel discussion on The Personal Genome. The Symposium featured Eric Lander, George Church, Leena Peltonen and Bill Gates and was moderated by Maynard Olson.

My take away from the discussion, which was fueled by questions submitted by the audience and via the web, was that there is so much uncertainty at this time. We know so much, yet so little. At some level, we do not understand the implications of what we know, ethical and medical, at the same time, we underestimate the ability of our own genetics to withstand changes.

Perhaps one of the things that jumped out at me was the general popular belief (which is hardly surprising) that it is a gene or a few genes that can be altered or fixed to address a “problem”. We’re just beginning to grasp the relevance of pathways, of epigenetics, etc, so the long term implications of what we know (and don’t) are still a little fuzzy.

I didn’t get a chance to record or take notes, but I was Twittering the whole thing. Unfortunately, I forgot to use a hashtag, which was silly. Much of the backchannel discussion was on the subject of designer babies. Leena Peltonen made some good points about the impact of genetic selection (we will not be able to alter germ lines), and whether it was desirable from the evolutionary perspective. George Church pointed out that people were going to do it anyway, much as they do today for sex selection or during IVF.

Bill Gates had an interesting opinion on the question of what a personal genome really means. He differentiated between an individual with money getting themselves genotyped or sequenced and between the ability to sequence individuals cheaply and in large quantities. The latter for him was much more important since it will help advance science and medicine. He is quite right of course, and it will be interesting to see how the ability to sequence individuals cheaply has an impact on research and clinical studies, where, in theory, in a few years it will be possible to just sequence everyone.

More on Sandra Porter’s blog

Image via Wikipedia

Technorati Tags: , ,

ShareThis

Improve Your Financial Health, Reduce Stress and Help Save the Planet [Highlight HEALTH]

Posted: 24 Apr 2008 09:30 PM CDT

With crude oil hitting a record high this week, gas prices here in the U.S. are soaring. According to CNN.com, the $100 fill-up has arrived in the United States.

Want to reduce your stress level, spend less money at the pump and do your part to help save the planet? Here’s one of the most simple yet effective tips that will accomplish all three: Slow Down.

Improve Your Financial Health: Use Less Gas

At highway speeds, wind resistance increases exponentially and fuel economy is reduced by approximately 4 miles per gallon for every 10 mile per hour increase [1]. Thus, the faster you drive, the more it will cost you. Consider this [1].

In a typical family sedan, every 10 miles per hour you drive over 60 is like the price of gasoline going up about 54 cents a gallon. That figure will be even higher for less fuel-efficient vehicles that go fewer miles on a gallon to start with.

slow downThat’s based on a $3.25 price per gallon, which is less than the current price of gas. So we’re talking more than 54 cents a gallon.

Additionally, if you do the math, speeding doesn’t save you anywhere near the time you might think it does. An average 30 mile commute traveling at 65 miles/hour takes 28 minutes, while that same trip at 80 miles/hour takes 23 minutes. You save a whole 5 minutes by driving 15 MPH faster.

How much money is that 5 minutes worth?

Reduce Stress and Stay Safe

Moderate levels of stress from a variety of sources, including other motorists, traffic congestion and roadway conditions, are common in everyday driving. However, driver stress has been shown to also be influenced by a combination of situational and personal factors, including factors external to the driving context [2].

Not surprisingly, studies have found that life stress is associated with higher rates of accidents and disease [3]. It’s been estimated that drivers who have experienced a recent stressful event are five times more likely to cause fatal accidents than unstressed drivers [4].

If you’re running late, remember that no matter how fast you drive, you’re still going to be late. If you’re under a great deal of personal stress, it’s probably best to avoid driving altogether.

Statistically, people who drive too fast cause or contribute to almost one-third of all fatal crashes. In 2006,13,543 lives were lost in speeding-related crashes [5]. Excessive speed does a number of things:

  • it increases the distance a vehicle travels when a driver reacts to a dangerous situation
  • it reduces a driver’s ability to steer safely around objects in the road
  • it extends the distance necessary to stop

Want to reduce your stress level, spend less money on gas and do your part to help save the planet?

      Just Slow Down!

David over at The Good Human has some additional tips on saving money, saving fuel and saving the environment.

References

  1. Slow down a little, save a lot of gas. Issue #1: America’s Money. CNN Money. 2008 Mar 27.
  2. Hennessy et al. The Influence of Traffic Congestion, Daily Hassles, and Trait Stress Susceptibility on State Driver Stress: An Interactive Perspective. Journal of Applied Biobehavioral Research 5(2);162–179
    doi: 10.1111/j.1751-9861.2000.tb00072.x
  3. Stuart and Brown. The relationship of stress and coping ability to incidence of diseases and accidents. Journal of Psychosomatic Research, 25(4), 255-260. 1981.
    View abstract
  4. Brenner and Selzer. Risk of causing a fatal accident associated with alcoholism, psychopathology, and stress: further analysis of previous data. Behav Sci. 1969 Nov;14(6):490-5.
    View abstract
  5. Traffic Safety Facts 2006 Data. National Highway Traffic Safety Administration National Center for Statistics and Analysis. 2006.
Thank you for subscribing by RSS or email. I work hard to make the articles on Highlight HEALTH engaging and I truly appreciate your interest and readership!

This article was published on Highlight HEALTH.

Related articles

Timely Release and A Unanimous Vote [The Gene Sherpa: Personalized Medicine and You]

Posted: 24 Apr 2008 08:49 PM CDT

First and foremost, everyone is jumping for joy since the Genetics Information and NonDiscrimination Act passed unanimously today. But, I will not rest until President Bush takes that lovely little...

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

No comments: